Stay updated with breaking news from Jessica cotrone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(0) CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, April 29, 2021 to report its first quarter 2021 financial results and discuss business highlights. To access the live conference call, please dial 866-795-3242. The archived webcast will be available on Evelo s website approximately two hours after the completion of the event and will be available for 30 days following the call. About Evelo Biosciences Evelo Biosciences is a clinical stage biotechnology company developing orally delivered medicines that act on SINTAX, the small intestinal axis, and to have systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company s first product candidates are pharmaceutical prepar ....
Evelo Biosciences, Inc.: Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis -Meaningful improvements over placebo on clinical scores, including new data released on key IGA endpoints- -Initiation of Phase 2 trial of EDP1815 in atopic dermatitis expected in 3Q 2021- CAMBRIDGE, Mass., April 20, 2021for all 24 patients in the cohort, which is re-iterated in the presentation, together with new data on the Investigator Global Assessment (IGA) score. The primary endpoint of the Phase 1b trial was safety and tolerability. As previously disclosed, EDP1815 was well tolerated, with no treatment-related adverse events of moderate or severe intensity and no serious adverse events. The full results reinforce the data released on January 20, 2021, demonstrating that treatment with EDP1815 resulted in clinically meaningful improvements in both patient- and physician-reported outcomes. At the day 70 follow-up visit, 31% mo ....
(0) CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointments of Luca Scavo as Chief Financial Officer (CFO), effective June 1, 2021, and Julie H. McHugh to its Board of Directors, effective immediately. Mr. Scavo brings more than 25 years of international experience in both emerging and developed markets within pioneering biotechnology and diagnostics companies including Genentech, Roche and AstraZeneca, where he led teams across diverse global markets and through different stages of a company s life cycle. He most recently served as Senior Vice President and CFO of Roche Diagnostics North America. ....
Evelo Biosciences, Inc.: Evelo Biosciences to Present at 20th Annual Needham Virtual Healthcare Conference finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.